AAPL325.28+9.94 (+3.15%) ▲|ABBV253.57+2.66 (+1.06%) ▲|ABT103.46-1.77 (-1.68%) ▼|ACN177.87+2.07 (+1.18%) ▲|ADBE249.01-5.85 (-2.30%) ▼|AMAT456.75-12.10 (-2.58%) ▼|AMD505.31-15.79 (-3.03%) ▼|AMGN382.46-8.82 (-2.25%) ▼|AMT172.51-2.92 (-1.66%) ▼|AMZN251.64-0.76 (-0.30%) ▼|AVGO361.91-2.47 (-0.68%) ▼|AXP320.62-1.18 (-0.37%) ▼|BA204.88-1.55 (-0.75%) ▼|BAC62.50-0.18 (-0.28%) ▼|BKNG174.23+0.80 (+0.46%) ▲|BLK1,062.91-9.12 (-0.85%) ▼|BMY63.92-0.50 (-0.77%) ▼|BNY162.53+0.02 (+0.01%) ▲|BRK-B506.43-0.29 (-0.06%) ▼|C138.20+0.40 (+0.29%) ▲|CAT803.92-11.64 (-1.43%) ▼|CL87.93-0.10 (-0.11%) ▼|CMCSA25.19+0.60 (+2.44%) ▲|COF207.00-3.86 (-1.83%) ▼|COP137.45+0.92 (+0.67%) ▲|COST901.51-1.09 (-0.12%) ▼|CRM242.83-1.33 (-0.54%) ▼|CSCO107.85-1.58 (-1.44%) ▼|CVS95.44+0.06 (+0.06%) ▲|CVX213.10-0.72 (-0.33%) ▼|DE677.02-0.20 (-0.03%) ▼|DHR201.03-3.83 (-1.87%) ▼|DIS105.12+0.94 (+0.90%) ▲|DUK119.59-0.85 (-0.70%) ▼|EMR147.71-2.63 (-1.75%) ▼|FDX311.71+2.52 (+0.82%) ▲|GD354.24+1.57 (+0.45%) ▲|GE323.54-1.88 (-0.58%) ▼|GEV923.32-27.72 (-2.91%) ▼|GILD144.92-0.73 (-0.50%) ▼|GM85.87+2.11 (+2.52%) ▲|GOOG330.30+1.92 (+0.58%) ▲|GOOGL332.68+2.03 (+0.61%) ▲|GS1,017.64-11.14 (-1.08%) ▼|HD305.04-5.41 (-1.74%) ▼|HON201.98-2.95 (-1.44%) ▼|IBM233.73-6.21 (-2.59%) ▼|INTC101.00-5.24 (-4.93%) ▼|INTU311.98-1.96 (-0.63%) ▼|ISRG360.87+7.63 (+2.16%) ▲|JNJ266.59-0.49 (-0.18%) ▼|JPM353.02-1.69 (-0.48%) ▼|KO88.00+0.45 (+0.51%) ▲|LIN461.04-5.62 (-1.20%) ▼|LLY1,123.98-0.23 (-0.02%) ▼|LMT528.40+3.94 (+0.75%) ▲|LOW196.31-2.29 (-1.15%) ▼|LRCX299.98-15.86 (-5.02%) ▼|MA564.61-2.89 (-0.51%) ▼|MCD252.96-0.52 (-0.21%) ▼|MDLZ62.28-0.14 (-0.22%) ▼|MDT91.62-0.27 (-0.29%) ▼|META643.23-10.47 (-1.60%) ▼|MMM162.74-1.66 (-1.01%) ▼|MO68.57+0.68 (+1.00%) ▲|MRK144.69-2.85 (-1.93%) ▼|MS213.33-2.02 (-0.94%) ▼|MSFT490.76-0.90 (-0.18%) ▼|MU981.93-45.84 (-4.46%) ▼|NEE82.68+0.03 (+0.04%) ▲|NFLX75.86-0.17 (-0.22%) ▼|NKE36.59-0.76 (-2.03%) ▼|NOW131.14+0.03 (+0.02%) ▲|NVDA218.38-5.29 (-2.37%) ▼|ORCL153.94-7.69 (-4.76%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.53-0.26 (-0.92%) ▼|PG143.06+0.42 (+0.30%) ▲|PLTR165.70-3.83 (-2.26%) ▼|PM189.55+3.84 (+2.07%) ▲|QCOM177.81+1.41 (+0.80%) ▲|RTX197.47-0.08 (-0.04%) ▼|SBUX99.40-0.65 (-0.64%) ▼|SCHW107.06+0.52 (+0.48%) ▲|SO88.07-0.28 (-0.31%) ▼|SPG205.23+0.70 (+0.34%) ▲|T25.62+0.47 (+1.87%) ▲|TMO602.65-3.05 (-0.50%) ▼|TMUS176.76-0.58 (-0.33%) ▼|TSLA363.84-3.98 (-1.08%) ▼|TXN258.73-2.86 (-1.09%) ▼|UBER72.38+1.30 (+1.83%) ▲|UNH389.44-3.62 (-0.92%) ▼|UNP285.24+0.50 (+0.18%) ▲|UPS99.84+0.62 (+0.62%) ▲|USB62.24+0.13 (+0.20%) ▲|V367.19-0.20 (-0.05%) ▼|VZ49.91+0.17 (+0.33%) ▲|WFC89.12-0.56 (-0.62%) ▼|WMT105.81-0.02 (-0.02%) ▼|XOM165.50+1.27 (+0.77%) ▲|AAPL325.28+9.94 (+3.15%) ▲|ABBV253.57+2.66 (+1.06%) ▲|ABT103.46-1.77 (-1.68%) ▼|ACN177.87+2.07 (+1.18%) ▲|ADBE249.01-5.85 (-2.30%) ▼|AMAT456.75-12.10 (-2.58%) ▼|AMD505.31-15.79 (-3.03%) ▼|AMGN382.46-8.82 (-2.25%) ▼|AMT172.51-2.92 (-1.66%) ▼|AMZN251.64-0.76 (-0.30%) ▼|AVGO361.91-2.47 (-0.68%) ▼|AXP320.62-1.18 (-0.37%) ▼|BA204.88-1.55 (-0.75%) ▼|BAC62.50-0.18 (-0.28%) ▼|BKNG174.23+0.80 (+0.46%) ▲|BLK1,062.91-9.12 (-0.85%) ▼|BMY63.92-0.50 (-0.77%) ▼|BNY162.53+0.02 (+0.01%) ▲|BRK-B506.43-0.29 (-0.06%) ▼|C138.20+0.40 (+0.29%) ▲|CAT803.92-11.64 (-1.43%) ▼|CL87.93-0.10 (-0.11%) ▼|CMCSA25.19+0.60 (+2.44%) ▲|COF207.00-3.86 (-1.83%) ▼|COP137.45+0.92 (+0.67%) ▲|COST901.51-1.09 (-0.12%) ▼|CRM242.83-1.33 (-0.54%) ▼|CSCO107.85-1.58 (-1.44%) ▼|CVS95.44+0.06 (+0.06%) ▲|CVX213.10-0.72 (-0.33%) ▼|DE677.02-0.20 (-0.03%) ▼|DHR201.03-3.83 (-1.87%) ▼|DIS105.12+0.94 (+0.90%) ▲|DUK119.59-0.85 (-0.70%) ▼|EMR147.71-2.63 (-1.75%) ▼|FDX311.71+2.52 (+0.82%) ▲|GD354.24+1.57 (+0.45%) ▲|GE323.54-1.88 (-0.58%) ▼|GEV923.32-27.72 (-2.91%) ▼|GILD144.92-0.73 (-0.50%) ▼|GM85.87+2.11 (+2.52%) ▲|GOOG330.30+1.92 (+0.58%) ▲|GOOGL332.68+2.03 (+0.61%) ▲|GS1,017.64-11.14 (-1.08%) ▼|HD305.04-5.41 (-1.74%) ▼|HON201.98-2.95 (-1.44%) ▼|IBM233.73-6.21 (-2.59%) ▼|INTC101.00-5.24 (-4.93%) ▼|INTU311.98-1.96 (-0.63%) ▼|ISRG360.87+7.63 (+2.16%) ▲|JNJ266.59-0.49 (-0.18%) ▼|JPM353.02-1.69 (-0.48%) ▼|KO88.00+0.45 (+0.51%) ▲|LIN461.04-5.62 (-1.20%) ▼|LLY1,123.98-0.23 (-0.02%) ▼|LMT528.40+3.94 (+0.75%) ▲|LOW196.31-2.29 (-1.15%) ▼|LRCX299.98-15.86 (-5.02%) ▼|MA564.61-2.89 (-0.51%) ▼|MCD252.96-0.52 (-0.21%) ▼|MDLZ62.28-0.14 (-0.22%) ▼|MDT91.62-0.27 (-0.29%) ▼|META643.23-10.47 (-1.60%) ▼|MMM162.74-1.66 (-1.01%) ▼|MO68.57+0.68 (+1.00%) ▲|MRK144.69-2.85 (-1.93%) ▼|MS213.33-2.02 (-0.94%) ▼|MSFT490.76-0.90 (-0.18%) ▼|MU981.93-45.84 (-4.46%) ▼|NEE82.68+0.03 (+0.04%) ▲|NFLX75.86-0.17 (-0.22%) ▼|NKE36.59-0.76 (-2.03%) ▼|NOW131.14+0.03 (+0.02%) ▲|NVDA218.38-5.29 (-2.37%) ▼|ORCL153.94-7.69 (-4.76%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.53-0.26 (-0.92%) ▼|PG143.06+0.42 (+0.30%) ▲|PLTR165.70-3.83 (-2.26%) ▼|PM189.55+3.84 (+2.07%) ▲|QCOM177.81+1.41 (+0.80%) ▲|RTX197.47-0.08 (-0.04%) ▼|SBUX99.40-0.65 (-0.64%) ▼|SCHW107.06+0.52 (+0.48%) ▲|SO88.07-0.28 (-0.31%) ▼|SPG205.23+0.70 (+0.34%) ▲|T25.62+0.47 (+1.87%) ▲|TMO602.65-3.05 (-0.50%) ▼|TMUS176.76-0.58 (-0.33%) ▼|TSLA363.84-3.98 (-1.08%) ▼|TXN258.73-2.86 (-1.09%) ▼|UBER72.38+1.30 (+1.83%) ▲|UNH389.44-3.62 (-0.92%) ▼|UNP285.24+0.50 (+0.18%) ▲|UPS99.84+0.62 (+0.62%) ▲|USB62.24+0.13 (+0.20%) ▲|V367.19-0.20 (-0.05%) ▼|VZ49.91+0.17 (+0.33%) ▲|WFC89.12-0.56 (-0.62%) ▼|WMT105.81-0.02 (-0.02%) ▼|XOM165.50+1.27 (+0.77%) ▲|
30.6 C
New York
Thursday, September 10, 2026

Tag: approval

newssourceFORcompanyinformationcontent1releasesmarket

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharma licensed FSU technology for Australian Chestnut Extract production and plans FDA discussions before refiling its NDIN.

newcleo Strengthens U.S. Leadership Team with Strategic Appointments of Dustin Greenwood and Travis Chapman

Industry veterans bring deep expertise in advanced reactor deployment, nuclear operations and regulatory licensing to support company’s U.S. growth 
Industry veterans bring deep expertise in advanced reactor deployment, nuclear operations and regulatory licensing to support company’s U.S. growth

Helius Minerals Announces Conditional Approval for the Acquisition of the Serra Pelada Gold – PGM Project

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, June 11, 2026 /CNW/ - Helius Minerals Limited...

Dana Incorporated Announces Agreement to Combine with Eaton’s Mobility Business, Strengthens Dana’s Position as a Leading Global Powertrain Systems Provider

Creates a premier, global powertrain leader focused on commercial and light vehicles with approximately $11 billion in sales and approximately $1.7 billion adjusted EBITDA...

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Crédit Agricole Financement de l’Habitat SFH : EARLY REPURCHASE OF ISIN FR001400JM17

Montrouge, June 11, 2026

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain...

TAIPEI, June 11, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil...

Regulatory release no. 4 – 2026: Correction. Result of InstallatørGruppen A/S’ Initial Public Offering on Nasdaq Copenhagen

                           

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

Regulatory release no. 3 – 2026: Stabilisation period begins

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

Canada Nickel Completes Upsized Non-Brokered Private Placement of Flow-Through Shares and Provides Corporate Update

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./TORONTO, June 10, 2026 /CNW/ - Canada...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsApproval

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers